Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Pfizer Internal
    Fellowship Internal Medicine Germany
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Androgen Deprivation Therapy (ADT) in Advanced Prostate Cancer
    Release Date:
    Partner: Myovant Sciences
    Review Process: Pfizer Internal
    Education Oncology USA
    Optimizing Biomarker-Directed Therapy in Metastatic Colorectal Cancer
    Release Date:
    Partner: The National Comprehensive Cancer Network®, Fight Colorectal Cancer
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Addressing the Needs of Patients with Mental Health Issues and Dermatological Inflammatory Conditions
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology Canada
    Quality Improvement Grants to Improve Identification and Management of Patients with ATTR-CM
    Release Date:
    Review Process: Pfizer Internal
    Translation: French (link)
    Quality Improvement Rare Disease Canada
    Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research
    Release Date:
    Review Process: Expert Review Panel
    Research Rare Disease USA
    Improving Treatment Environment and Survivorship for Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Improving Treatment Environment and Survivorship for Leukemia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Advances in the Management of Ulcerative Colitis (UC) (Europe, Canada, Japan, South Korea, Australia, New Zealand, Israel)
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    Increasing Awareness and Understanding of Transthyretin Cardiomyopathy (ATTR-CM)
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Shared Decision-Making (SDM) for Patient Quality of Life in Cancer Treatment and Improving Access to Biologics
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Improvement of Treatment Environment of Immuno-Oncology Therapy for Urothelial Cancer
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Japan
    Optimizing the management of mBC HER2-patients / Oncology
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Oncology Italy